Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05380713 | ......SMARTEST Trial...... | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05005429 | Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma(BIMES) | completed | Phase 2 | 47 | Fundación GECPOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07282873 | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 219 | TYK Medicines, IncINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02611037 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05730816 | MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI(MAGIC-AKI) | recruiting | Phase 2 | 130 | Brigham and Women's HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT04914897 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | terminated | Phase 2 | 106 | SanofiINDUSTRY | 11 | Oct 2, 2025 | clinicaltrials |
| NCT04400539 | The IMmunotherapy Pleural 5-ALA PDT(IMPALA) | recruiting | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05932199 | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | recruiting | Phase 1 / Phase 2 | 52 | Baylor College of MedicineOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | terminated | Phase 2 | 37 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 19, 2025 | clinicaltrials |
| NCT05449366 | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma(INTERACT MESO) | completed | Phase 1 / Phase 2 | 7 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT07131345 | Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma | not yet recruiting | Phase 1 / Phase 2 | 55 | National Cancer Center, ChinaOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT00354393 | Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 9 | The Cleveland ClinicOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06790082 | The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma(FAPI-PM) | recruiting | Phase 2 | 70 | Aalborg University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT02078700 | Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. | completed | Phase 2 | 40 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma | recruiting | Phase 2 | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05455424 | Niraparib Efficacy in Patient With Unresectable Mesothelioma(NERO) | completed | Phase 2 | 88 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04515836 | Olaparib in Patients With HRD Malignant Mesothelioma | recruiting | Phase 2 | 56 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT02649829 | Autologous Dendritic Cell Vaccination in Mesothelioma(MESODEC) | completed | Phase 1 / Phase 2 | 28 | University Hospital, AntwerpOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03560973 | A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM(RAMES) | completed | Phase 2 | 164 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04177953 | Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery | completed | Phase 2 | 92 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02784171 | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 / Phase 3 | 520 | Canadian Cancer Trials GroupNETWORK | 3 | Dec 10, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04287829 | Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients(PEMMELA) | active not recruiting | Phase 2 | 58 | The Netherlands Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT01265433 | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | completed | Phase 2 | 41 | Sellas Life Sciences GroupINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT05660616 | Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 40 | Ain Shams UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06543069 | Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | recruiting | Phase 2 | 28 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03319537 | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | terminated | Phase 1 / Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06416930 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | not yet recruiting | Phase 2 | 59 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT03502746 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | terminated | Phase 2 | 34 | Arkadiusz Z. Dudek, MDOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | not yet recruiting | Phase 2 | 63 | Oncotelic Inc.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04300244 | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma(NIPU) | active not recruiting | Phase 2 | 118 | Åslaug HellandOTHER | 5 | Feb 29, 2024 | clinicaltrials |
| NCT05930665 | Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | terminated | Phase 2 | 35 | Verastem, Inc.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03393858 | Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma | terminated | Phase 1 / Phase 2 | 10 | Capital Medical UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03610360 | DENdritic Cell Immunotherapy for Mesothelioma(DENIM) | completed | Phase 2 / Phase 3 | 176 | Amphera BVINDUSTRY | 5 | Feb 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 29, 2025source: clinicaltrials